The Onco Life Podcast

Lasofoxifene and ER+ Breast Cancer: Breakthroughs in Bone Metastasis Therapy

In this episode, we explore the latest advances in treating estrogen receptor-positive (ER+) breast cancer, with a spotlight on lasofoxifene, a next-generation hormonal therapy showing promise for patients with advanced disease and bone metastasis.

You’ll learn:

  • Why is such a common site for ER+ breast cancer metastasis
  • How traditional endocrine therapies can weaken bone health and impact quality of life
  • The unique dual action of lasofoxifene in both breast and bone tissue
  • Key insights from the ELAINE-1, ELAINE-2, and ELAINE-3 clinical trials
  • How lasofoxifene could reshape treatment for ESR1-mutated breast cancers
  • Potential benefits beyond tumor control, including bone protection and fewer side effects
  • The role of combination therapies with CDK4/6 and PI3K inhibitors in improving outcomes
  • How future research in immune competence and precision oncology may refine treatment strategies

With its ability to suppress tumor growth while preserving bone density, lasofoxifene represents a promising shift in ER+ breast cancer therapy, one that prioritizes both survival and quality of life.

Blog Link: New Advances in ER+ Breast Cancer Therapy

Send us a text

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.